Cost of illness of medically treated benign prostatic hyperplasia in Hungary

Fanni Rencz, Ágnes Kovács, Valentin Brodszky, L. Gulácsi, Zalán Németh, Gábor János Nagy, János Nagy, István Buzogány, Géza Böszörményi-Nagy, Attila Majoros, P. Nyírády

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To perform a cost of illness study in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) in Hungary. Methods: A multicentre, cross-sectional survey was carried out in 2014. BPH patients who had never undergone prostate surgery were recruited to the study. EQ-5D and the International Prostate Symptom Score (IPSS) were used to evaluate health status and disease severity. All resource utilisations related to BPH in the past 12 months were recorded. Cost analysis was performed from societal perspective. Results: Overall, 246 patients were included with mean age of 70.6 (SD 8.1) years. Mean EQ-5D and IPSS were 0.85 (SD 0.19) and 12.8 (SD 6.3). Total annual per patient cost of BPH amounted to €876 (SD €1829). Distribution of the costs between direct medical, direct non-medical and indirect cost was 46, 31 and 23 %. High costs were related to informal care (€243), medications (€178) and private physician visits (€132). Patients missed from work on average 14 h/year and 20 h/year due to absenteeism and presenteeism. Clinical severity expressed in IPSS score was found the strongest predictor of higher total costs (r = 0.429, p 

Original languageEnglish
Pages (from-to)1241-1249
Number of pages9
JournalInternational Urology and Nephrology
Volume47
Issue number8
DOIs
Publication statusPublished - Aug 31 2015

Fingerprint

Cost of Illness
Hungary
Prostatic Hyperplasia
Costs and Cost Analysis
Prostate
Absenteeism
Lower Urinary Tract Symptoms
Health Status
Patient Care
Cross-Sectional Studies
Physicians

Keywords

  • Benign prostatic hyperplasia
  • Cost of illness
  • EQ-5D
  • Healthcare costs
  • Lower urinary tract symptoms

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Cost of illness of medically treated benign prostatic hyperplasia in Hungary. / Rencz, Fanni; Kovács, Ágnes; Brodszky, Valentin; Gulácsi, L.; Németh, Zalán; Nagy, Gábor János; Nagy, János; Buzogány, István; Böszörményi-Nagy, Géza; Majoros, Attila; Nyírády, P.

In: International Urology and Nephrology, Vol. 47, No. 8, 31.08.2015, p. 1241-1249.

Research output: Contribution to journalArticle

Rencz, F, Kovács, Á, Brodszky, V, Gulácsi, L, Németh, Z, Nagy, GJ, Nagy, J, Buzogány, I, Böszörményi-Nagy, G, Majoros, A & Nyírády, P 2015, 'Cost of illness of medically treated benign prostatic hyperplasia in Hungary', International Urology and Nephrology, vol. 47, no. 8, pp. 1241-1249. https://doi.org/10.1007/s11255-015-1028-7
Rencz, Fanni ; Kovács, Ágnes ; Brodszky, Valentin ; Gulácsi, L. ; Németh, Zalán ; Nagy, Gábor János ; Nagy, János ; Buzogány, István ; Böszörményi-Nagy, Géza ; Majoros, Attila ; Nyírády, P. / Cost of illness of medically treated benign prostatic hyperplasia in Hungary. In: International Urology and Nephrology. 2015 ; Vol. 47, No. 8. pp. 1241-1249.
@article{64d4610f3ce447588980737303523f50,
title = "Cost of illness of medically treated benign prostatic hyperplasia in Hungary",
abstract = "Objective: To perform a cost of illness study in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) in Hungary. Methods: A multicentre, cross-sectional survey was carried out in 2014. BPH patients who had never undergone prostate surgery were recruited to the study. EQ-5D and the International Prostate Symptom Score (IPSS) were used to evaluate health status and disease severity. All resource utilisations related to BPH in the past 12 months were recorded. Cost analysis was performed from societal perspective. Results: Overall, 246 patients were included with mean age of 70.6 (SD 8.1) years. Mean EQ-5D and IPSS were 0.85 (SD 0.19) and 12.8 (SD 6.3). Total annual per patient cost of BPH amounted to €876 (SD €1829). Distribution of the costs between direct medical, direct non-medical and indirect cost was 46, 31 and 23 {\%}. High costs were related to informal care (€243), medications (€178) and private physician visits (€132). Patients missed from work on average 14 h/year and 20 h/year due to absenteeism and presenteeism. Clinical severity expressed in IPSS score was found the strongest predictor of higher total costs (r = 0.429, p ",
keywords = "Benign prostatic hyperplasia, Cost of illness, EQ-5D, Healthcare costs, Lower urinary tract symptoms",
author = "Fanni Rencz and {\'A}gnes Kov{\'a}cs and Valentin Brodszky and L. Gul{\'a}csi and Zal{\'a}n N{\'e}meth and Nagy, {G{\'a}bor J{\'a}nos} and J{\'a}nos Nagy and Istv{\'a}n Buzog{\'a}ny and G{\'e}za B{\"o}sz{\"o}rm{\'e}nyi-Nagy and Attila Majoros and P. Ny{\'i}r{\'a}dy",
year = "2015",
month = "8",
day = "31",
doi = "10.1007/s11255-015-1028-7",
language = "English",
volume = "47",
pages = "1241--1249",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "8",

}

TY - JOUR

T1 - Cost of illness of medically treated benign prostatic hyperplasia in Hungary

AU - Rencz, Fanni

AU - Kovács, Ágnes

AU - Brodszky, Valentin

AU - Gulácsi, L.

AU - Németh, Zalán

AU - Nagy, Gábor János

AU - Nagy, János

AU - Buzogány, István

AU - Böszörményi-Nagy, Géza

AU - Majoros, Attila

AU - Nyírády, P.

PY - 2015/8/31

Y1 - 2015/8/31

N2 - Objective: To perform a cost of illness study in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) in Hungary. Methods: A multicentre, cross-sectional survey was carried out in 2014. BPH patients who had never undergone prostate surgery were recruited to the study. EQ-5D and the International Prostate Symptom Score (IPSS) were used to evaluate health status and disease severity. All resource utilisations related to BPH in the past 12 months were recorded. Cost analysis was performed from societal perspective. Results: Overall, 246 patients were included with mean age of 70.6 (SD 8.1) years. Mean EQ-5D and IPSS were 0.85 (SD 0.19) and 12.8 (SD 6.3). Total annual per patient cost of BPH amounted to €876 (SD €1829). Distribution of the costs between direct medical, direct non-medical and indirect cost was 46, 31 and 23 %. High costs were related to informal care (€243), medications (€178) and private physician visits (€132). Patients missed from work on average 14 h/year and 20 h/year due to absenteeism and presenteeism. Clinical severity expressed in IPSS score was found the strongest predictor of higher total costs (r = 0.429, p 

AB - Objective: To perform a cost of illness study in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) in Hungary. Methods: A multicentre, cross-sectional survey was carried out in 2014. BPH patients who had never undergone prostate surgery were recruited to the study. EQ-5D and the International Prostate Symptom Score (IPSS) were used to evaluate health status and disease severity. All resource utilisations related to BPH in the past 12 months were recorded. Cost analysis was performed from societal perspective. Results: Overall, 246 patients were included with mean age of 70.6 (SD 8.1) years. Mean EQ-5D and IPSS were 0.85 (SD 0.19) and 12.8 (SD 6.3). Total annual per patient cost of BPH amounted to €876 (SD €1829). Distribution of the costs between direct medical, direct non-medical and indirect cost was 46, 31 and 23 %. High costs were related to informal care (€243), medications (€178) and private physician visits (€132). Patients missed from work on average 14 h/year and 20 h/year due to absenteeism and presenteeism. Clinical severity expressed in IPSS score was found the strongest predictor of higher total costs (r = 0.429, p 

KW - Benign prostatic hyperplasia

KW - Cost of illness

KW - EQ-5D

KW - Healthcare costs

KW - Lower urinary tract symptoms

UR - http://www.scopus.com/inward/record.url?scp=84938284777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938284777&partnerID=8YFLogxK

U2 - 10.1007/s11255-015-1028-7

DO - 10.1007/s11255-015-1028-7

M3 - Article

VL - 47

SP - 1241

EP - 1249

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 8

ER -